The NTCP-inhibitor Myrcludex B : effects on bile acid disposition and tenofovir pharmacokinetics

enthalten in: Clinical pharmacology & therapeutics | 2018

von Blank, A. | Eidam, A. | Hohmann, N. | +8

CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers

in: Clinical pharmacology & therapeutics | 2014

von Markert, C. | Burhenne, J. | Weiß, J. | +2

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions

enthalten in: Clinical pharmacology & therapeutics | 20 March 2013

von Halama, B. | Hohmann, N. | Burhenne, J. | +3

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis

enthalten in: Clinical pharmacology & therapeutics | 03 August 2011

von Ngaimisi, E. | Mugusi, S. | Minzi, O. | +10

Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy

enthalten in: Clinical pharmacology & therapeutics | 21 September 2011

von Katzenmaier, S. | Markert, C. | Riedel, K. | +3

Effect of simultaneous induction and inhibition of CYP3A by St John's wort and ritonavir on CYP3A activity

enthalten in: Clinical pharmacology & therapeutics | 2010

von Hafner-Blumenstiel, V. | Jäger, M. | Matthée, A. | +4

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir

enthalten in: Clinical pharmacology & therapeutics | 28 February 2007

von Josephson, F. | Allqvist, A. | Janabi, M. | +9

Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

enthalten in: Clinical pharmacology & therapeutics | 19 August 2006

von Mikus, G. | Schöwel, V. | Ten Hoevel, M. | +7

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

enthalten in: Clinical pharmacology & therapeutics | 2006

von Mikus, G. | Schöwel, V. | Drzewinska, M. | +7

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

enthalten in: Clinical pharmacology & therapeutics | 25 July 2005

von Rengelshausen, J. | Banfield, M. | Riedel, K. | +6